NEW YORK – Indian precision oncology firm 4baseCare said this week that its genomics lab at Dubai Science Park has been accredited by the College of American Pathologists. The lab was established in partnership with United Arab Emirates-based next-generation sequencing provider Innovate Life Sciences. The two firms inked a deal last fall to offer 4baseCare’s genomic tests in Dubai.
Flatiron Health said this week that it is collaborating with NRG Oncology — a clinical research consortium in the National Cancer Institute's National Clinical Trials Network (NCTN) — to use Flatiron Clinical Pipe in a multicenter NRG clinical trial. Flatiron Clinical Pipe software connects electronic health records (EHRs) to electronic data capture, improving efficiency and reducing the time and effort involved in clinical study data entry, Flatiron said. Flatiron's EHR-to-EDC technology is expected to reduce the burden on NRG clinical trial site teams, streamline data management, and accelerate study timelines. In parallel, NRG and Flatiron will conduct a correlative study to assess the efficiency of Flatiron Clinical Pipe use compared to traditional data entry methods.
Primo Partners this week said it partnered with ABX Advanced Biochemical Compounds to market its imaging diagnostic Radelumin in Taiwan. The product, called PB01 in Taiwan, detects prostate specific membrane antigen (PSMA) to allow doctors to identify and monitor prostate cancer. It is used for early detection, staging, and recurrence monitoring in high-risk prostate cancer.
Circular Genomics said this week that it is moving its corporate headquarters to Lilly Gateway Labs in San Diego, which is operated in partnership with Alexandria Real Estate Equities. Gateway Labs is an innovation hub that connects biotech companies to Eli Lilly's expertise. The company will use these resources to advance the development of diagnostic and prognostic blood tests for Alzheimer's disease based on the company's circular RNA (circRNA) biomarker technology. In September, Circular Genomics launched the early-access program for MindLight, its first circRNA biomarker-based blood test designed to predict the likelihood of whether a patient with major depressive disorder (MDD) will respond, or not, to selective serotonin reuptake inhibitor (SSRI) antidepressant treatment.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on Precision Medicine Online.